Iron Chelation in Thalassemia Major

Clinical Therapeutics

Volumn 37, Issue 12, 2015, Pages 2866-2877

  Borgna Pignatti, Caterina ^a   Marsella, Maria ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b G RUMMO HOSPITAL   (Italy)

Author keywords

iron chelators; iron overload; labile plasma iron; Thalassemia major

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; IRON; IRON CHELATING AGENT;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; AGRANULOCYTOSIS; ARTHRALGIA; ARTHROPATHY; ARTICLE; BLEEDING; BONE MALFORMATION; CATARACT; DIARRHEA; DIGESTIVE SYSTEM ULCER; DRUG COST; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; ERYTHROPOIESIS; FANCONI RENOTUBULAR SYNDROME; GROWTH RETARDATION; HEARING IMPAIRMENT; HUMAN; INCREASED APPETITE; INJECTION SITE REACTION; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; KIDNEY TUBULE DISORDER; KLEBSIELLA PNEUMONIAE INFECTION; LACTOSE INTOLERANCE; MEDICATION COMPLIANCE; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCEPTION DEAFNESS; PREGNANCY; PROTEINURIA; QUALITY OF LIFE; THALASSEMIA MAJOR; TUBULAR DYSFUNCTION; VISUAL DISORDER; VOMITING; YERSINIA PSEUDOTUBERCULOSIS INFECTION; YERSINIOSIS; ZINC DEFICIENCY; BETA-THALASSEMIA; BLOOD; CHELATION THERAPY;

BETA-THALASSEMIA; CHELATION THERAPY; HUMANS; IRON; IRON CHELATING AGENTS;

EID: 84950236966     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.10.001     Document Type: Review

References (72)

1. R. Galanello, and R. Origa Beta-thalassemia Orphanet J Rare Dis 5 2010 11
2. B.P. Esposito, W. Breuer, P. Sirankapracha, and et al. Labile plasma iron in iron overload: redox activity and susceptibility to chelation Blood 102 2003 2670 2677
3. C. Borgna-Pignatti, and M.R. Gamberini Complications of thalassemia major and their treatment Expert Rev Hematol 4 2011 353 366
4. M. Casale, S. Citarella, A. Filosa, and et al. Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major Am J Hematol 89 2014 1102 1106
5. C. Borgna-Pignatti, S. Rugolotto, P. De Stefano, and et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine Haematologica 89 2004 1187 1193
6. G.Y. Oudit, H. Sun, M.G. Trivieri, and et al. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy Nat Med 9 2003 1187 1194
7. J.B. Porter Pathophysiology of transfusional iron overload: contrasting patterns in thalassemia major and sickle cell disease Hemoglobin 33 Suppl 1 2009 S37 S45
8. J.C. Wood, B.P. Kang, A. Thompson, and et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores Blood 116 2010 537 543
9. V. Chirico, L. Rigoli, A. Lacquaniti, and et al. Endocrinopathies, metabolic disorders, and iron overload in major and intermedia thalassemia: serum ferritin as diagnostic and predictive marker associated with liver and cardiac T2∗MRI assessment Eur J Haematol 94 2015 404 412
10. T.G. St Pierre, A. El-Beshlawy, M. Elalfy, and et al. Multicenter validation of spin-density projection-assisted R2-MRI for the noninvasive measurement of liver iron concentration Magn Reson Med 71 2014 2215 2223
11. A. Ramazzotti, A. Pepe, V. Positano, and et al. Multicenter validation of the magnetic resonance T2∗technique for segmental and global quantification of myocardial iron J Magn Reson Imaging 30 2009 62 68
12. L.J. Anderson, S. Holden, B. Davis, and et al. Cardiovascular T2-star (T2∗) magnetic resonance for the early diagnosis of myocardial iron overload Eur Heart J 22 2001 2171 2179
13. L.J. Noetzli, S.D. Mittelman, R.M. Watanabe, and et al. Pancreatic iron and glucose dysregulation in thalassemia major Am J Hematol 87 2012 155 160
14. L.J. Noetzli, A. Panigrahy, S.D. Mittelman, and et al. Pituitary iron and volume predict hypogonadism in transfusional iron overload Am J Hematol 87 2012 167 171
15. M.A. Tanner, R. Galanello, C. Dessi, and et al. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation J Cardiovasc Magn Reson 8 2006 543 547
16. S.A. Fisher, S.J. Brunskill, C. Doree, and et al. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia Cochrane database Syst Rev 2013 8 CD004450
17. N.F. Olivieri, G. Koren, J. Harris, and et al. Growth failure and bony changes induced by deferoxamine Am J Pediatr Hematol Oncol 14 1992 48 56
18. S. De Virgiliis, M. Congia, F. Frau, and et al. Deferoxamine-induced growth retardation in patients with thalassemia major J Pediatr 113 1988 661 669
19. T.V. Adamkiewicz, M. Berkovitch, C. Krishnan, and et al. Infection due to Yersinia enterocolitica in a series of patients with beta-thalassemia: incidence and predisposing factors Clin Infect Dis 27 1998 1362 1366
20. B.H.Y. Chung, S.Y. Ha, G.C.F. Chan, and et al. Klebsiella infection in patients with thalassemia Clin Infect Dis 36 2003 575 579
21. F.N. Al-Refaie, C. Hershko, A.V. Hoffbrand, and et al. Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators Br J Haematol 91 1995 224 229
22. a.V. Hoffbrand, A. Taher, and M.D. Cappellini How I treat transfusional iron overload Blood 120 2012 3657 3669
23. A.R. Cohen, R. Galanello, A. Piga, and et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone Blood 102 2003 1583 1587
24. S. Dadheech, A.V. Rao, U. Shaheen, and et al. Three most common nonsynonymous UGT1A6∗2 polymorphisms (Thr181Ala, Arg184Ser and Ser7Ala) and therapeutic response to deferiprone in β-thalassemia major patients Gene 531 2013 301 305
25. D. Chirnomas, A.L. Smith, J. Braunstein, and et al. Deferasirox pharmacokinetics in patients with adequate versus inadequate response Blood 114 2009 4009 4013
26. J.L. Kwiatkowski, H.-Y. Kim, A.A. Thompson, and et al. Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort Blood 119 2012 2746 2753
27. M.D. Cappellini, M. Bejaoui, L. Agaoglu, and et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up Blood 118 2011 884 893
28. S.A. Fisher, S.J. Brunskill, C. Doree, and et al. Oral deferiprone for iron chelation in people with thalassaemia Cochrane database Syst Rev 2013 8 CD004839
29. D.J. Pennell, J.B. Porter, A. Piga, and et al. A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA) Blood 123 2014 1447 1455
30. A. Taher, M.S. Elalfy, K. Al Zir, and et al. Importance of optimal dosing ≥ 30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia Eur J Haematol 87 2011 355 365
31. L. Dubourg, C. Laurain, B. Ranchin, and et al. Deferasirox-induced renal impairment in children: an increasing concern for pediatricians Pediatr Nephrol 27 2012 2115 2122
32. J. Yacobovich, P. Stark, S. Barzilai-Birenbaum, and et al. Acquired proximal renal tubular dysfunction in β-thalassemia patients treated with deferasirox J Pediatr Hematol Oncol 32 2010 564 567
33. M.A. Tanner, R. Galanello, C. Dessi, and et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction J Cardiovasc Magn Reson 10 2008 12
34. P. Evans, R. Kayyali, R.C. Hider, and et al. Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone Transl Res 156 2010 55 67
35. R. Galanello, A. Kattamis, A. Piga, and et al. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia Haematologica 91 2006 1241 1243
36. P.T. Telfer, F. Warburton, S. Christou, and et al. Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone Haematologica 94 2009 1777 1778
37. A. Maggio, A. Vitrano, M. Capra, and et al. Improving survival with deferiprone treatment in patients with thalassemia major: A prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies Blood Cells Mol Dis 42 2009 247 251
38. K. Farmaki, I. Tzoumari, C. Pappa, and et al. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major Br J Haematol 148 2010 466 475
39. R.W. Grady, R. Galanello, R.E. Randolph, and et al. Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine Haematologica 98 2013 129 135
40. E. Cassinerio, N. Orofino, A. Roghi, and et al. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients Blood Cells Mol Dis 53 2014 164 167
41. A. Lal, J. Porter, N. Sweeters, and et al. Combined chelation therapy with deferasirox and deferoxamine in thalassemia Blood Cells Mol Dis 50 2013 99 104
42. E. Voskaridou, D. Christoulas, and E. Terpos Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies Br J Haematol 154 2011 654 656
43. Elalfy, Adly AM, Wali Y, et al. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferipronre in severely iron-overloaded young beta thalassemia major patients. Eur J Haematol. 2015;95:411-20.
44. K. Farmaki, I. Tzoumari, and C. Pappa Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications Blood Cells Mol Dis 47 2011 33 40
45. M. Balocco, P. Carrara, V. Pinto, and G.L. Forni Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients Am J Hematol 85 2010 460 461
46. C. Borgna-Pignatti, A. Meloni, G. Guerrini, and et al. Myocardial iron overload in thalassaemia major How early to check? Br J Haematol 164 2014 579 585
47. M.S. ElAlfy, M. El Alfy, T.T. Sari, and et al. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload J Pediatr Hematol Oncol 32 2010 601 605
48. D. Songdej, N. Sirachainan, P. Wongwerawattanakoon, and et al. Combined chelation therapy with daily oral deferiprone and twice-weekly subcutaneous infusion of desferrioxamine in children with β-thalassemia: 3-year experience Acta Haematol 133 2014 226 236
49. V. Viprakasit, I. Nuchprayoon, A. Chuansumrit, and et al. Deferiprone (GPO-L-ONE(®)) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand Am J Hematol 88 2013 251 260
50. Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients - Full Text View - ClinicalTrials.gov. http://clinicaltrial.gov/ct2/show/NCT01825512?term=deferiprone&rank=16. Accessed May 6, 2015.
51. M. Marsella, C. Borgna-Pignatti, a. Meloni, and et al. Cardiac iron and cardiac disease in males and females with transfusion-dependent thalassemia major: a T2∗magnetic resonance imaging study Haematologica 96 2011 515 520
52. D.J. Pennell, J.E. Udelson, A.E. Arai, and et al. Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association Circulation 128 2013 281 308
53. D.J. Pennell, V. Berdoukas, M. Karagiorga, and et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis Blood 107 2006 3738 3744
54. A. Piga, C. Gaglioti, E. Fogliacco, and F. Tricta Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis Haematologica 88 2003 489 496
55. C. Borgna-Pignatti, M.D. Cappellini, P. De Stefano, and et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major Blood 107 2006 3733 3737
56. D.J. Pennell, J.B. Porter, A. Piga, and et al. Sustained improvements in myocardial T2∗over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine Am J Hematol 90 2015 91 96
57. Z.I. Cabantchik Labile iron in cells and body fluids: physiology, pathology, and pharmacology Front Pharmacol 5 2014 45
58. J.B. Porter, J. Wood, N. Olivieri, and et al. Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone J Cardiovasc Magn Reson 15 2013 38
59. C. Borgna-Pignatti, M.C. Garani, G.L. Forni, and et al. Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry Br J Haematol 167 2014 121 126
60. M.D. Cappellini A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia Blood 107 2006 3455 3462
61. J.B. Porter, M.S. Elalfy, A.T. Taher, and et al. Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy Ann Hematol 92 2013 211 219
62. E. Cassinerio, A. Roghi, N. Orofino, and et al. A 5-year follow-up in deferasirox treatment: improvement of cardiac and hepatic iron overload and amelioration in cardiac function in thalassemia major patients Ann Hematol 94 2015 939 945
63. F. Danjou, R. Origa, F. Anni, and et al. Longitudinal analysis of heart and liver iron in thalassemia major patients according to chelation treatment Blood Cells Mol Dis 51 2013 142 145
64. J.C. Wood, T. Glynos, a. Thompson, and et al. Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial Haematologica 96 2011 1055 1058
65. T.D. Coates Bad liver and a broken heart Blood 123 2014 1434 1436
66. F. Pinna, R. Carta, M. Morittu, and et al. Thalassemia major: who is afraid of serum ferritin below 500 μg/L? Acta Haematol 134 2015 183 184
67. S.T. Singer, and E.P. Vichinsky Deferoxamine treatment during pregnancy: is it harmful? Am J Hematol 60 1999 24 26
68. A. Ceci, L. Mangiarini, M. Felisi, and et al. The management of iron chelation therapy: preliminary data from a national registry of thalassaemic patients Anemia 2011 2011 435683
69. M. Marsella, and C. Borgna-Pignatti Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease Hematol Oncol Clin North Am 28 2014 703 727 vi
70. A. Bentley, S. Gillard, M. Spino, and et al. Cost-utility analysis of deferiprone for the treatment of β-thalassaemia patients with chronic iron overload: a UK perspective Pharmacoeconomics 31 2013 807 822
71. F.L. Trachtenberg, E. Gerstenberger, Y. Xu, and et al. Relationship among chelator adherence, change in chelators, and quality of life in thalassemia Qual Life Res 23 2014 2277 2288
72. Guidelines for the Management of Transfusion Dependent Thalassemia (TDT) Third Edition TIF publication no. 20 2014 Thalassemia international foundation Nicosia, Cyprus